首頁 > 市場調查報告書 > 製藥

呼吸器

遺傳性慢性阻塞性肺病 (COPD) 市場，按藥物類別、給藥途徑、分銷渠道、地區 - 規模、份額、前景、機會分析，2023-2030 年

市場調查報告書

商品編碼

1233364

遺傳性慢性阻塞性肺病 (COPD) 市場，按藥物類別、給藥途徑、分銷渠道、地區 - 規模、份額、前景、機會分析，2023-2030 年

Genetic Chronic Obstructive Pulmonary Disease Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年01月27日 | 出版商:

Coherent Market Insights | 英文 178 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

與 alpha-1 缺乏相關的肺氣腫稱為遺傳性。慢性阻塞性肺病 (COPD) 涉及肺部炎症，可導致肺部氣流受阻。它是一種慢性疾病，症狀包括喘息、粘液分泌和呼吸困難。慢性支氣管炎、肺氣腫和頑固性哮喘都是 COPD 的症狀，COPD 是一種肺部退行性疾病。慢性阻塞性肺病 (COPD) 最常由吸煙、空氣污染、二手煙和 alpha-1 缺乏相關肺氣腫（一種罕見的 COPD 形式）引起。

每年，有數百萬人患有慢性阻塞性肺病，簡稱 COPD。肺氣腫和慢性支氣管炎是兩種統稱為慢性阻塞性肺病的疾病。在肺氣腫中，肺部的氣囊（稱為肺泡）受損。運動時呼吸急促是肺氣腫的第一個徵兆。甚至在休息時也可能出現呼吸困難。慢性阻塞性肺病 (COPD) 的四個階段從輕微到非常嚴重。症狀包括持續咳嗽、呼吸急促和喘息。

市場動態

市場主要參與者越來越多地採用有機策略，例如產品發布和批准，預計將在預測期內推動市場增長。例如，2020 年 9 月，製藥公司 GSK, Plc. 和專注於醫療保健的資產管理公司 Innoviva Inc. 宣布，美國食品藥品監督管理局 (FDA) 已批准 Trelegy Ellipta（氟替卡松漂浮物/烏克溴銨/維蘭特羅）。FF/UMEC/VI”）用於治療 18 歲及以上患者的哮喘，擴大批准用於當前患有慢性阻塞性肺疾病（COPD）的患者。 Trelegy Ellipta 不適用於緩解急性支氣管痙攣。此外，還有多種針對 COPD 呼吸系統疾病的前瞻性藥物正在研發中，有望推動全球遺傳性角化阻塞性肺病（COPD）市場的增長。

這項研究的主要特點

本報告對全球遺傳性慢性阻塞性肺疾病 (COPD) 治療市場進行了深入分析，揭示了以 2022 年為基準年的預測期 (2023-2030) 的市場規模和復合年增長率。 (CAGR%) 發布。
它還闡明了各個細分市場的潛在創收機會，並描述了該市場具有吸引力的投資建議矩陣。
它還提供了市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭戰略的關鍵考慮因素。本文根據以下參數介紹了全球遺傳性慢性阻塞性肺病 (COPD) 治療市場主要參與者的概況：公司亮點、產品組合、主要亮點、財務業績和戰略。
本研究涵蓋的主要公司 GSK Plc.、AstraZeneca Plc.、Merck (Sigma-Aldrich)、Dey Pharma、Grifols, S.A.、Teva Pharmaceutical Industries Ltd、Baxter、Boehringer Ingelheim International GmbH、Kamada Ltd、Takeda Pharmaceutical Company Limited、LFB SA、Abeona Therapeutics、Alnylam Pharmaceuticals, Inc.、Vertex Pharmaceuticals Incorporated、Kedrion S.p.A. 和 Arrowhead Pharmaceuticals, Inc.
這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
《全球遺傳性慢性阻塞性肺疾病 (COPD) 治療市場報告》面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
利益相關者可以通過用於分析全球遺傳性慢性阻塞性肺疾病 (COPD) 治療市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

調查目的
先決條件
縮寫

第二章市場概況

報告內容
- 市場定義和範圍
執行摘要
- 市場概況：按藥物類別
- 按給藥途徑劃分的市場概況
- 市場概況：按分銷渠道
- 市場概況：按地區
連貫機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

市場動態
- 司機
- 約束因素
- 市場機會
監管情景
主要亮點
關於研發合作夥伴關係和併購
害蟲分析
管道解析
流行病學

第 4 章遺傳性慢性阻塞性肺疾病 (COPD) 的全球市場 - 冠狀病毒 (COVID-19) 大流行的影響

總體影響
政府舉措
COVID-19 對市場的影響

第 5 章按藥物類別劃分的全球遺傳性慢性阻塞性肺疾病 (COPD) 市場：2017-2030

支氣管擴張劑
4 型磷酸二酯□抑製劑
類固醇
抗生素
其他

第 6 章。按給藥途徑劃分的全球遺傳性慢性阻塞性肺疾病 (COPD) 市場：2017-2030

口語
鼻音

第 7 章。全球遺傳性慢性阻塞性肺疾病 (COPD) 市場，按分銷渠道，2017-2030

醫院藥房
零售藥房
在線藥店

第 8 章全球遺傳性慢性阻塞性肺疾病 (COPD) 市場按地區劃分，2017-2030

北美
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地區
歐洲
英國
德國
意大利
法國
西班牙
俄羅斯
其他歐洲
亞太地區
中國
印度
日本
東盟
澳大利亞
韓國
其他亞太地區
中東
海灣合作委員會
以色列
其他中東地區
非洲
北非
中非
南非

第9章競爭格局

熱圖分析
公司簡介
- GSK Plc
- AstraZeneca Plc
- Merck（Sigma-Aldrich）
- Dey Pharma
- Grifols, S.A.
- Teva Pharmaceutical Industries Ltd
- Baxter
- Boehringer Ingelheim International GmbH
- Kamada Ltd
- Takeda Pharmaceutical Company Limited
- LFB SA
- Abeona Therapeutics
- Alnylam Pharmaceuticals, Inc.
- Vertex Pharmaceuticals Incorporated
- Kedrion S.p.A.
- Arrowhead Pharmaceuticals, Inc

第 10 章

參考文獻
調查方法

簡介目錄

Product Code: CMI5512

Alpha-1 deficiency-related emphysema is called as genetic Chronic obstructive pulmonary disease (COPD) involves lung inflammation, causing obstruction of airflow from the lungs. It is a chronic illness, and some of its symptoms include wheezing, mucus production, and breathing difficulties. Chronic bronchitis, emphysema, and refractory asthma are all symptoms of COPD, a degenerative lung condition. Chronic obstructive pulmonary disease (COPD) is mostly brought on by smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (a rare form of COPD), and other factors.

Each year, millions of people are affected by chronic obstructive pulmonary disease, or COPD for short. Emphysema and chronic bronchitis are two conditions that are collectively referred to as COPD. The lungs' alveoli, which are air sacs, suffer damage in emphysema. Breathlessness while exercising is the first sign of emphysema. Later, breathing difficulties can also happen while at rest. The four stages of chronic obstructive pulmonary disease (COPD) range from mild to very severe. Some symptoms may include an ongoing cough, shortness of breath, and wheezing.

Market Dynamics

Increasing adoption of organic strategies by key players in market such as product launch and approval is expected to drive market growth over the forecast period. For instance, in September 2020, GSK, Plc.,a pharmaceutical company and Innoviva Inc., a healthcare focused asset management company, announced that the U.S. Food and Drug Administration (FDA) approved a new indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the treatment of asthma in patients 18 years and older, expanding the current approval for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for the relief of acute bronchospasm. Moreover, several prospective drugs, primarily for COPD, are in the pipeline for respiratory illnesses, which is anticipated to boost growth of the global genetic chornic obstructive pulmonary disease (COPD) market.

Key features of the study:

This report provides an in-depth analysis of the global genetic chronic obstructive pulmonary disease (COPD) treatment market, and provides market size (us$ million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
it profiles key players in the global genetic chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study GSK Plc., AstraZeneca Plc., Merck (Sigma-Aldrich), Dey Pharma, Grifols, S.A., Teva Pharmaceutical Industries Ltd, Baxter, Boehringer Ingelheim International GmbH, Kamada Ltd, Takeda Pharmaceutical Company Limited, LFB SA, Abeona Therapeutics, Alnylam Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Kedrion S.p.A., and Arrowhead Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global genetic chronic obstructive pulmonary disease (COPD) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global genetic chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation:

Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class:
- Bronchodilators
- Phosphodiesterase Type 4 Inhibitors
- Steroids
- Antibiotics
- Others
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration:
- Oral
- Nasal
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- GSK Plc*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AstraZeneca Plc
- Merck (Sigma-Aldrich)
- Dey Pharma
- Grifols, S.A.
- Teva Pharmaceutical Industries Ltd
- Baxter
- Boehringer Ingelheim International GmbH
- Kamada Ltd
- Takeda Pharmaceutical Company Limited.
- LFB SA
- Abeona Therapeutics
- Alnylam Pharmaceuticals, Inc.
- Vertex Pharmaceuticals Incorporated
- Kedrion S.p.A.
- Arrowhead Pharmaceuticals, Inc

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route Of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Regulatory Scenario
Key Highlights
Research and Development Collaboration, Mergers, and Acquisitions
PEST Analysis
Pipeline Analysis
Epidemiology

4. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market - Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Drug Class, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Bronchodilators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Phosphodiesterase Type 4 Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Steroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Route Of Administration, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Nasal
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa